KDP:NASDAQKeurig Dr Pepper Inc. Analysis
Data as of 2026-05-21 - not real-time
$28.48
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Keurig Dr Pepper delivered first‑quarter 2026 results that topped consensus estimates, propelling the share price up roughly 7.7% in after‑hours trading. Revenue rose 9.4% year‑over‑year to $16.94 billion, supported by a solid 53.8% gross margin and a 19.0% operating margin. Net profit margin held at 10.8% and earnings per share came in at $1.35, beating forecasts. The company also announced a quarterly dividend of $0.92, yielding about 3.2% and reinforcing its income‑oriented appeal. Analyst consensus remains a “buy” with a median price target of $33, implying roughly a 16.8% upside from the current $28.48 price. The stock now trades just above the calculated support level of $27.84, giving a modest technical cushion.
Valuation metrics show a forward P/E of 11.3 versus a trailing P/E of 21.1, suggesting the shares are undervalued relative to earnings expectations. The forward‑looking price‑to‑book of 1.53 and a dividend payout ratio of 68% are in line with peers in the consumer defensive space. Beta is exceptionally low (≈0.14), indicating limited price sensitivity to market swings, while 30‑day volatility sits near 30%, reflecting short‑term price swings. Volume trends are decreasing, which could temper liquidity, but the market cap of $38.7 billion provides a solid liquidity base. A high debt‑to‑equity ratio (≈86) and negative free cash flow raise concerns about long‑term cash generation. Overall, the blend of earnings momentum, attractive dividend yield, and a sizable upside target supports a favorable near‑term outlook, tempered by balance‑sheet pressures.
Valuation metrics show a forward P/E of 11.3 versus a trailing P/E of 21.1, suggesting the shares are undervalued relative to earnings expectations. The forward‑looking price‑to‑book of 1.53 and a dividend payout ratio of 68% are in line with peers in the consumer defensive space. Beta is exceptionally low (≈0.14), indicating limited price sensitivity to market swings, while 30‑day volatility sits near 30%, reflecting short‑term price swings. Volume trends are decreasing, which could temper liquidity, but the market cap of $38.7 billion provides a solid liquidity base. A high debt‑to‑equity ratio (≈86) and negative free cash flow raise concerns about long‑term cash generation. Overall, the blend of earnings momentum, attractive dividend yield, and a sizable upside target supports a favorable near‑term outlook, tempered by balance‑sheet pressures.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 8/10
Key Factors
- Q1 earnings beat expectations
- Current price above technical support with upside potential
- Strong dividend yield
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward P/E discount to peers
- Analyst median target price implying ~16% upside
- Stable consumer defensive positioning
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- High debt-to-equity and negative free cash flow
- Potential dividend sustainability concerns
- Brand portfolio resilience in a defensive sector
Key Metrics & Analysis
Financial Health
Revenue Growth9.40%
Profit Margin10.81%
P/E Ratio21.1
ROE6.31%
ROA3.61%
Debt/Equity85.98
P/B Ratio1.5
Op. Cash Flow$2.1B
Free Cash Flow$-16345499648
Technical Analysis
TrendNeutral
RSI50.9
Support$27.84
Resistance$29.68
MA 20$28.90
MA 50$27.45
MA 200$28.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.16
Valuation
Target Price$33.25
Upside/Downside16.77%
GradeUndervalued
TypeBlend
Dividend Yield3.20%
Risk Assessment
Beta0.14
Volatility29.78%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.